Table 4.
Multivariate analysis for locoregional recurrence‐free survival
| HR | 95% confidence interval | P valuea | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Subtype | ||||
| Luminal A | 1 | |||
| Luminal B | 2.313 | 0.665 | 8.04 | .1900 |
| HER2‐positive | 5.034 | 1.357 | 18.67 | .0160 |
| TNBC | 5.188 | 1.335 | 20.16 | .0170 |
| Grade | ||||
| 1‐2 | 1 | |||
| 3 | 0.899 | 0.396 | 2.04 | .8000 |
| pT | ||||
| 1 | 1 | |||
| 2 | 0.713 | 0.334 | 1.52 | .3800 |
| 3 | 1.785 | 0.511 | 6.24 | .3600 |
| pN | ||||
| 0 | 1 | |||
| 1 | 1.947 | 0.363 | 10.45 | .4400 |
| 2 | 2.654 | 0.514 | 13.72 | .2400 |
| 3 | 9.607 | 2.053 | 44.96 | .0041 |
| LVI | ||||
| 0 | 1 | |||
| 1 | 0.993 | 0.443 | 2.22 | .9900 |
Isolated distant metastasis and death as competing risks.
Abbreviations: TNBC, triple‐negative breast cancer; LVI, lymphatic vessel invasion.
a
Significance of hazard ratio (HR) was calculated with Fine and Gray's competing risk regression model.